Skip to main content
SpringerLink
Log in

Pregnancy outcome in women exposed to dopamine agonists during pregnancy: a pharmacoepidemiology study in EFEMERIS database

  • Maternal-Fetal Medicine
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose

The objective of this exposed–unexposed study was to evaluate potential effects of dopamine agonists during pregnancy.

Methods

Data from EFEMERIS, a cohort of 57,408 pregnant women living in South West France, were used to compare exposed and unexposed women. The exposed group included 183 women (0.3 %) who received at least one prescription for one dopamine agonist during pregnancy. These women were individually matched with two unexposed women from the cohort for age and the month-and-year of the start of pregnancy. Pregnancy losses, birth defects, preterm births, low birth weight and psychomotor development were studied.

Results

Bromocriptine was the most frequently prescribed dopamine agonist, followed by cabergoline and quinagolide. Most (75 %) of the dopamine agonists were prescribed at the beginning of pregnancy (first trimester). There was no difference between the two groups concerning pregnancy history and demographic data. After adjustment for potential confounders, prescription and dispensation of dopamine agonists was associated with an increased risk of pregnancy loss [PORa = 3.7; 95 % confidence interval (CI) 1.8–7.4] and preterm birth (PORa = 3.6; 95 % CI 1.5–8.3). The prevalence of birth defects and low birth weight was not significantly different between the two groups. No difference in psychomotor development at either 9 or 24 months was observed between the two groups.

Conclusion

This study suggests that prenatal exposure to dopamine agonists may be associated with an increased risk of pregnancy loss and preterm birth.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kars M, Souverein PC, Herings RMC et al (2009) Estimated age- and gender-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab 94(8):2729–2734

    Article  CAS  PubMed  Google Scholar 

  2. Elbaz A, Bower JH, Maraganore DM et al (2002) Risk tables for parkinsonism and Parkinson’s disease. J Clin Epidemiol 55(1):25–31

    Article  PubMed  Google Scholar 

  3. Sundström E, Kölare S, Souverbie F et al (1993) Neurochemical differentiation of human bulbospinal monoaminergic neurons during the first trimester. Brain Res Dev Brain Res 75(1):1–12

    Article  PubMed  Google Scholar 

  4. Herlenius E, Lagercrantz H (2004) Development of neurotransmitter systems during critical periods. Exp Neurol 190(Suppl 1):S8–S21

    Article  CAS  PubMed  Google Scholar 

  5. Lacroix I, Hurault C, Sarramon MF et al (2009) Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol 65(8):839–846

    Article  CAS  PubMed  Google Scholar 

  6. Beck S, Wojdyla D, Say L et al (2010) The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. Bull World Health Org 88(1):31–38

    Article  PubMed Central  PubMed  Google Scholar 

  7. WHO health status statistics: morbidity. http://www.who.int/healthinfo/statistics/indlowbirthweight/en/index.html. Accessed 17 Dec 2012

  8. Les certificats de santé aux 8e jour, 9e mois et 24e mois—Drees—Ministère des Affaires sociales et de la Santé. http://www.drees.sante.gouv.fr/les-certificats-de-sante-aux-8e-jour-9e-mois-et-24e-mois,7333.html. Accessed 18 Feb 2013

  9. Krupp P, Monka C (1987) Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 65(17):823–827

    Article  CAS  PubMed  Google Scholar 

  10. Stalldecker G, Mallea-Gil MS, Guitelman M et al (2010) Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature. Pituitary 13(4):345–350

    Article  CAS  PubMed  Google Scholar 

  11. Colao A, Abs R, Bárcena DG, Chanson P, Paulus W, Kleinberg DL (2008) Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol (Oxf) 68(1):66–71

    Article  CAS  Google Scholar 

  12. Ricci E, Parazzini F, Motta T et al (2002) Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 16(6):791–793

    Article  CAS  PubMed  Google Scholar 

  13. Källen B, Olausson Otterblad P, Danielsson BR (2005) Is erythromycin therapy teratogenic in humans? Reprod Toxicol 20(2):209–214

    Article  PubMed  Google Scholar 

  14. Turkalj I, Braun P, Krupp P (1982) Surveillance of bromocriptine in pregnancy. JAMA 247(11):1589–1591

    Article  CAS  PubMed  Google Scholar 

  15. Estan L, Berenquer A, Martinez-Mir I, Rubio E, Morales-Olivas FJ (1993) Response to dopamine agonists of the rat isolated uterus. Gen Pharmacol 24:397–401

    Article  CAS  PubMed  Google Scholar 

  16. Estan L, Martinez-Mir I, Rubio E, Morales-Olivas FJ (1988) Relaxant effect of dopamine on the isolated rat uterus. Naunyn Schmiedebergs Arch Pharmacol 338:484–488

    Article  CAS  PubMed  Google Scholar 

  17. Gobello C (2006) Dopamine agonists, anti-progestins, anti-androgens, long-term-release GnRH agonists and anti-estrogens in canine reproduction: a review. Theriogenology 66:1560–1567

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

We declare that we have no conflict of interest.

Author information

Authors and Affiliations

  1. Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d’Informations sur le Médicament, INSERM UMR 1027, Faculté de Médecine, Université Toulouse 3, Centre Hospitalier Universitaire, 37 allées Jules Guesde, 31000, Toulouse, France

    Caroline Hurault-Delarue, Jean-Louis Montastruc, Anna-Belle Beau, Isabelle Lacroix & Christine Damase-Michel

Authors
  1. Caroline Hurault-Delarue
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-Louis Montastruc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna-Belle Beau
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Isabelle Lacroix
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christine Damase-Michel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Caroline Hurault-Delarue.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 15 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hurault-Delarue, C., Montastruc, JL., Beau, AB. et al. Pregnancy outcome in women exposed to dopamine agonists during pregnancy: a pharmacoepidemiology study in EFEMERIS database. Arch Gynecol Obstet 290, 263–270 (2014). https://doi.org/10.1007/s00404-014-3210-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-014-3210-z

Keywords

Search

Navigation